- Home
- CVAC vs TCPC Comparison
CVAC vs TCPC Comparison
Compare CVAC & TCPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVAC
- TCPC
- Stock Information
- Founded
- CVAC 2000
- TCPC 2006
- Country
- CVAC Germany
- TCPC United States
- Employees
- CVAC N/A
- TCPC N/A
- Industry
- CVAC Biotechnology: Pharmaceutical Preparations
- TCPC Finance/Investors Services
- Sector
- CVAC Health Care
- TCPC Finance
- Exchange
- CVAC Nasdaq
- TCPC Nasdaq
- Market Cap
- CVAC 1.2B
- TCPC 603.8M
- IPO Year
- CVAC 2020
- TCPC 2012
- Fundamental
- Price
- CVAC $5.35
- TCPC $6.65
- Analyst Decision
- CVAC Hold
- TCPC Sell
- Analyst Count
- CVAC 3
- TCPC 2
- Target Price
- CVAC $6.83
- TCPC $6.75
- AVG Volume (30 Days)
- CVAC 473.7K
- TCPC 530.9K
- Earning Date
- CVAC 11-11-2025
- TCPC 11-05-2025
- Dividend Yield
- CVAC N/A
- TCPC 18.33%
- EPS Growth
- CVAC N/A
- TCPC N/A
- EPS
- CVAC 1.01
- TCPC N/A
- Revenue
- CVAC $599,540,810.00
- TCPC $239,535,768.00
- Revenue This Year
- CVAC N/A
- TCPC N/A
- Revenue Next Year
- CVAC $23.95
- TCPC N/A
- P/E Ratio
- CVAC $5.33
- TCPC N/A
- Revenue Growth
- CVAC 675.15
- TCPC 3.11
- 52 Week Low
- CVAC $2.37
- TCPC $6.27
- 52 Week High
- CVAC $5.72
- TCPC $9.72
- Technical
- Relative Strength Index (RSI)
- CVAC 44.68
- TCPC 31.14
- Support Level
- CVAC $5.34
- TCPC $7.09
- Resistance Level
- CVAC $5.41
- TCPC $6.79
- Average True Range (ATR)
- CVAC 0.04
- TCPC 0.13
- MACD
- CVAC -0.00
- TCPC -0.05
- Stochastic Oscillator
- CVAC 33.33
- TCPC 11.27
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
About TCPC BlackRock TCP Capital Corp.
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights or direct equity investments.